Octimet raises EUR 11.3M in series A
Cancer play Octimet Oncology N.V. (Beerse, Belgium) raised EUR 11.3 million ($12 million) in a series A financing led by V-Bio Ventures and Fund+. DROIA Oncology Ventures and OMNES Capital also participated.
Octimet has licensed small molecule inhibitors of c-Met receptor tyrosine kinase (c-MET, MET, HGFR, c-Met proto-oncogene) from the Janssen Pharmaceutica N.V. unit of Johnson & Johnson (NYSE:JNJ). Its lead program, selective MET inhibitor OMO-1, has completed a Phase I trial in healthy volunteers. The company intends to study the candidate in patients with MET biomarkers, as monotherapy or in combination with targeted agents and standard of care to treat solid tumors...
BCIQ Target Profiles
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)